Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market

Future Market Insights

Key Insight

The nucleic acid and gene therapies in neuromuscular disorders market is projected to grow from USD 9.4 billion in 2025 to USD 23.4 billion by 2035, at a CAGR of 9.5%. Myopathies including Muscular Dystrophies will dominate with a 36.8% market share, while aav gene therapy will lead the therapy segment with a 42.5% share.

August 21, 2025

Anurag Sharma

280 Pages

Cite this Report

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market

https://www.futuremarketinsights.com/reports/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Arctoris Limited
Benitec Biopharma Ltd
Celsion Corporation
Established in 2013
Founded in 2020
Nucleic Acid
PYC Therapeutics Ltd

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Market

Key Players

Similar Industry Reports